10.11588/data/10092
Rème, ThierryEmde, MartinaSeckinger, AnjaHose, Dirk
HDAMM-predictor: prediction of progression in asymptomatic myeloma patients
heiDATA
2016
doi:10.11588/data/10092/GWWWNLdoi:10.11588/data/10092/1OTQUNdoi:10.11588/data/10092/SC0BZGdoi:10.11588/data/10092/VJGBZDdoi:10.11588/data/10092/MVFR84doi:10.11588/data/10092/R0DQYU
The HDAMM-predictor is based on microarray gene expression and predicts the risk of progression from asymptomatic to symptomatic myeloma. It divides the patients in three groups, from low to high risk to progress. It was generated according to the method published by Rème et al. 2013. Gene expression profiles of 259 asymptomatic myeloma patients were used as trainingset.
Priv.-Doz. Dr. med. Dr. biol. hom. Dirk Hose, Medizinische Klinik V, Universitätsklinikum Heidelberg, Im Neuenheimer Feld 410, 69120 Heidelberg, 49-6221-566140Rème, ThierryEmde, MartinaSeckinger, AnjaHose, Dirk